

Neurizon Secures R&D Tax Incentive Advance & Overseas Finding Approval for NUZ-001

Highlights:

- **Neurizon® has been awarded an Advance and Overseas Finding from AusIndustry for eligible overseas R&D expenditure for NUZ-001 for the 2025, 2026 and 2027 financial years**
- **Covers all NUZ-001 development costs in ALS and other neurodegenerative diseases — spanning pre-clinical, manufacturing, regulatory, and clinical programs, including the HEALEY ALS Platform Trial**
- **The 43.5% cash rebate for eligible R&D expenditure accelerates timelines, further de-risks the NUZ-001 development program towards approval, and provides a significant source of non-dilutive funding**
- **For FY2025, an estimated total R&D Tax Rebate of AUD\$5.6 million is expected to be received in Q4 CY2025**

18 September 2025 – Melbourne Australia: Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has been awarded an Advance & Overseas Finding (AOF) from AusIndustry. This confirms that planned overseas research and development (R&D) expenditure for the 2025, 2026 and 2027 financial years for NUZ-001 is claimable under the Australian Federal Government's R&D Tax Incentive Program (R&D Tax Rebate).

The AOF is binding on the Commissioner of Taxation and AusIndustry¹ for the 2025, 2026 and 2027 financial years and means that in addition to eligible Australian R&D expenditure, planned overseas R&D expenditure is now eligible for a 43.5% cash rebate². This includes all pre-clinical, manufacturing, regulatory and clinical development expenditure for NUZ-001 in ALS and other neurodegenerative diseases, as well as the HEALEY ALS Platform Trial.

The approved AOF supports an expected R&D Tax Rebate of approximately \$5.6m for the 2025 financial year. As previously disclosed to the market, Neurizon has already secured a loan of AUD\$1.5m against this refund through Radium Capital, a specialist R&D financier, and anticipates receiving a net amount of approximately AUD\$4.1m (before interest and fees) in Q4 CY2025.

Chief Financial Officer, Mr Dan O'Connell commented: "This Advance and Overseas Finding is a strong validation of Neurizon's development pathway for NUZ-001, our lead candidate in ALS and related neurodegenerative diseases. It directly supports our ability to execute pivotal clinical trials and enhances investor confidence by providing a substantial, non-dilutive funding stream. Importantly, it enables us to accelerate timelines while reducing risk, ensuring we can keep momentum in bringing NUZ-001 closer to patients who urgently need new treatment options."

For people living with ALS and their families, every step forward counts. This approval represents not only financial strength for Neurizon but also a meaningful step towards advancing therapies that can potentially make a real difference."

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

¹ The Advance and Overseas Finding is binding on both AusIndustry and the Commissioner in relation to the eligibility of the activities.

² The eligibility of foreign R&D expenditure for the R&D Tax In is reliant of the planned and actual activities undertaken by Neurizon remaining aligned with the activities detailed in the Advance and Overseas Finding application and Neurizon remaining eligible to receive the R&D Tax Incentive rebate.

For further information, please contact:

Neurizon Therapeutics

Dr Michael Thurn
CEO & Managing Director
enquiries@neurizon.com
+61 (3) 9692 7222

Neurizon Therapeutics

Lidija Damjanovic
Marketing & Corporate Affairs
lidija@neurizon.com
+61 (0) 425 700 504

Investor Relations

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited